Download presentation
Presentation is loading. Please wait.
Published byGeorgia Butler Modified over 9 years ago
1
{ The Evaluation of Weakness in the Electromyography Lab Anthony Chiodo, MD, MBA University of Michigan Health System AAPMR Meeting, San Diego
2
38 year old right handed woman comes in with a chief complaint of weakness Noticed it first in her inability to complete her usual circuit training program over the last month Subsequently affected her aerobic exercise program and day to day home management activities Case Study
3
She does not think there has been any numbness or tingling She has not noticed it affecting one area of the body first but is uncertain She has had no new pain, no fever or chills, no change in bowel or bladder control
4
Past medical history is remarkable for hypothyroidism for which she takes synthroid Family history is significant for a maternal grandmother with rheumatoid arthritis, paternal grandparents with diabetes mellitus and heart disease, father with hypertension, mother with hypothyroidism
5
Deep tendon reflexes are 1+ Pin sensation and light touch is symmetric Strength testing shows shoulder and hip girdle muscles in the 3-4 range, hamstrings 3, elbows 4, hands and feet 4+ to 5 There is no tenderness and no pain with ROM Physical Examination
6
{ Differential Diagnosis
7
{ Neuromuscular Junction Disorders Anthony Chiodo, M.D.
8
Motor disorder Defect affecting the relationship between the distal motor axon and muscle Defect can be pre-synaptic, synaptic, or post- synaptic Acquired disorders are pre- or post-synaptic NMJ Disorders: Nature of the Abnormality
9
Normal distally and conduction Sensory Nerve Conduction Studies
10
Post-synaptic: Normal Pre-synaptic: inability to achieve transmission: decreased motor evoked amplitudes but normal latency and conduction Motor Nerve Conduction Studies
11
Pre-synaptic: if no motor units are seen with activation, fibrillation potentials and positive waves are possible Botulism Otherwise, decreased amplitude motor units of varying amplitude and rapid recruitment Post-synaptic: varying amplitude motor units with rapid recruitment If myasthenia gravis: may see proximal fibrillation potentials and positive waves Routine Needle Examination
12
{ Repetitive Nerve Stimulation Physiology is Key to Understanding
13
Molecules = Quanta X # Released(p) Typical Quanta = several thousand acetylcholine molecules, generate MEPP, amplitude 1 mV P typically around 60 quanta released per nerve stimulus Muscle action potentials at 7-20 mV Presynaptic Acetylcholine Stores
14
Reserve: 300,000 quanta Mobilization: 10,000 quanta Immediate Release: 1,000 quanta Types of Acetylcholine Stores
15
Mobilization store: 1500 msec Reserve: 3-4 minutes Time Availability
16
Decreased quanta released per nerve stimulation Synaptic vesicle fusion time(Ca++ dependent) is 100-200 msec Maximal decrement at 2-3 Hz No decrement at 10 Hz Normal decrement < 8% Concept of Decrement
17
1 st stimulus: 60 quanta 2 nd stimulus: 56 quanta 3 rd stimulus: 53 quanta 4 th stimulus: 55 quanta as reserve quanta become available Accounts for decrease in EPP and results in increase risk of failure (blocking) over four repetitive stimulations at 2 Hz At 2 Hz Repetitive Stimulation
18
Other Disorders NMJ Transmission Myotonia Neurogenic Disorders with Denervation/Reinnervation Rapidly Progressive ALS Polyneuropathy Mononeuropathy Radiculopathy What Other Disorders Have a Decrement To Low Frequency Repetitive Nerve Stimulation?
19
Yes, temperature Increased decrement and blocking at increased temperature due to increased acetylcholinesterase activity May account for the fact that the effect is more pronounced in proximal muscles Are there any physiological parameters that effect this finding?
20
Acetylcholine Receptor Antibodies Normal number of MEPP’s MEPP amplitude decreased by 80% Post-activation facilitation Post-activation exhaustion Myasthenia Gravis
22
Increased calcium in endplate increases the quanta released Decrement decreased, small increase in motor evoked amplitude Post-activation Facilitation
23
Depletion of mobilization and immediate release stores, before reserve store becomes available Decreased receptor excitability Characteristic of Myasthenia Gravis Post-activation Exhaustion
25
Recording surface 25 mcm to pick up from single muscle fiber Quantify the differences in time of onset of firing of two muscle fibers from the same motor unit Jitter is the mean difference in this firing onset time Blocking is the rate of failure of a muscle fiber from firing with it’s motor unit SFEMG
27
Pre- and post- synaptic neuromuscular junction disorders Ongoing neuropathic processes: motor neuron disease, neuropathy, radiculopathy Diagnoses with Increased Jitter
28
Hallmark: Fluctuating weakness Diplopia Ophthalmoplegia Ptosis Facial Weakness Dysphagia Vocal cord weakness Respiratory muscle weakness Pelvic floor muscle weakness Myasthenia Gravis Clinical Symptoms
30
I:Ocular IIA:Mild generalized IIB:Moderate generalized III:Acute severe with bulbar symptoms IV:Late severe V:Muscle atrophy Clinical Classifications of Myasthenia Gravis Severity: Osserman
32
Active:5-7 years Inactive:10 years Burned Out:Slow improvement seen 40-50% of ocular myasthenics will become generalized in the first 2 years Clinical Course in Myasthenia Gravis
33
Antibodies: 80% generalized, 55% ocular Seronegative: 70% with anti-MuSK Ig Rep Stim: 76% generalized, 48% ocular Limb SFEMG: 89% generalized, 60% ocular Facial SFEMG: 92% ocular Myasthenia Gravis Diagnosis
34
Evaluate/treat other autoimmune disorders: RA, thyroid, B-12 Pacing High K+ diet Avoid excessive heat>cold Watch for cyclic changes in women Avoid botox, quinamm, aminoglycosides, tetracyclines, anesthetic agents, anticonvulsants Preventing Exacerbations in Myasthenia Gravis
35
Mestinon: Acetylcholinesterase inhibitor Prednisone Imuran, Cytoxan, Cyclosporine, Mycophenolate Therapeutic Plasma Exchange Thymectomy AchR-based Immunoadsorbants Mucosal injection of AchR-recombinant fragments IG to proinflammatory cytokine IL-18 and costimulatory factor CD40L Create viral manipulated antigen presenting cells that express AchR to present to AchR-specific T- cells and activate Fas ligand “guided missile” Myasthenia Gravis Treatment
36
Creatine plus resistance exercise with normal treatment in mild MG shows improved strength and muscle mass Isometric exercise effective in improving strength in mild MG Exercise in Myasthenia Gravis
37
Increased acetylcholinesterase activity Decreased sensitivity of acetylcholine receptors More rapid presynaptic acetylcholine depletion Can explain proximal>distal weakness Effect of Temperature in Myasthenia Gravis
38
Antibodies prevent pre-synaptic Ca++ influx prevents quanta release Decreased number of MEPP’s of normal amplitude Decrement to low frequency rep stim due to many muscle fibers activated near-threshold so decreased release is miniscule but significant Post-exercise facilitation due to increased Ca++ in cell resulting in increased quanta release with next nerve stimulus Myasthenic Syndrome
39
Immunogenic: responds to TPE, prednisone, and 2,4-DAP Tumorogenic: responds to cancer therapy Eaton-Lambert Types
40
Food, wound or infantile Markedly decreased pre-synaptic release due to botulinum toxin binding to and entry into the nerve terminus membrane Cleave proteins in synaptic vesicle membrane inhibiting release Complete binding may result in no increment to exercise Complete binding may lead to fibrillation potentials and positive waves Botulism
41
LEMS: hallmark is marked incremental response with exercise AIDP Critical illness myopathy Botulism Differential Diagnosis
42
Does not include neonatal myasthenia gravis Presynaptic: failed production, storage and mobilization of acetylcholine Acetylcholine receptors: decreased number, decreased binding, prolonged binding/opening Congenital absence of acetycholinesterase Congenital Myasthenia Gravis
43
Thank you!
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.